{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-123286","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.155859+00:00","generated_at":"2026-05-30T03:54:05.887734+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tyra Biosciences Q3 net loss $24M; cash $360M; positive interim TYRA-300 mUC data","bullets":["Net loss $24.0M in Q3 2024 vs $21.2M in Q3 2023; R&D expense $22.7M, up from $19.3M.","Cash, equivalents, and marketable securities $360.1M; runway through at least 2026.","TYRA-300 interim data: at ≥90 mg QD, 6/11 (54.5%) mUC patients with FGFR3+ had confirmed PR; 100% disease control.","FDA cleared IND for Phase 2 achondroplasia study (BEACH301); first child dosing expected Q1 2025.","Appointed Doug Warner as Chief Medical Officer, effective September 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-123286","json":"https://secwatch.observer/filing/0000950170-24-123286.json","markdown":"https://secwatch.observer/filing/0000950170-24-123286.md","text":"https://secwatch.observer/filing/0000950170-24-123286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024123286/0000950170-24-123286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024123286/tyra-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:54:05.887734+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}